Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04470427 · ClinicalTrials.gov registry record · Phase 3

A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19

A Phase 3 study of SARS-CoV-2, sponsored by ModernaTX.

Completed
Registry status
Phase 3
Development phase
30,415
Enrollment target
20
Study locations

NCT04470427 is a Phase 3 study of SARS-CoV-2 that has completed, run by ModernaTX. The registered enrollment target is 30,415 participants, above the 2,684-participant average among 28 other SARS-CoV-2 trials with a reported enrollment target (1033% higher). The trial reports 20 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04470427, a Phase 3 study of SARS-CoV-2, has completed, sponsored by ModernaTX.

COMPLETED
Registry status
Phase 3
Development phase
30,415 participants
Enrollment target
20
Study locations

Study Summary

The mRNA-1273 vaccine is being developed to prevent COVID-19, the disease resulting from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection. The study is designed to primarily evaluate the efficacy, safety, and immunogenicity of mRNA-1273 to prevent COVID-19 for up to 2 years after the second dose of mRNA-1273.

Conditions Studied

SARS-CoV-2

Interventions

  • BIOLOGICAL Placebo
  • BIOLOGICAL mRNA-1273

Study Locations (20)

California

  • Advanced Clinical Research - Rancho Paseo - Banning
  • University of California San Diego - La Jolla
  • eStudySite - La Mesa - La Mesa
  • UCLA Vine Street Clinic CRS - Los Angeles
  • VA Greater Los Angeles Healthcare (veterans only) - Los Angeles
  • Paradigm Clinical Research Institute Inc - Redding
  • Benchmark Research - Sacramento - Sacramento
  • Medical Center For Clinical Research - M3 Wake Research - San Diego

Arizona

  • Hope Research Institute - Chandler
  • Synexus Clinical Research US, Inc. - Phoenix West - Glendale
  • Hope Research Institute - Peoria
  • Hope Research Institute - Phoenix
  • Quality of Life Medical and Research Center - Tucson

Alabama

  • Ascension St. Vincent Birmingham - Birmingham
  • Synexus Clinical Research US, Inc. - Birmingham - Birmingham

Colorado

  • University of Colorado Hospital - Aurora
  • Lynn Institute of The Rockies - Colorado Springs

Arkansas

  • Baptist Health Center for Clinical Research - Little Rock

District of Columbia

  • George Washington University - Washington D.C.

Florida

  • Accel Research Site - DeLand

Trial Details

FieldValue
Enrollment Target 30,415 participants
Start Date 2020-07-27
Est. Completion 2022-12-29
Phase Phase 3

Sponsor

ModernaTX

90 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04470427

The ClinicalTrials.gov registry entry for NCT04470427 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 30,415 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 2,684-participant average among 28 other SARS-CoV-2 trials with a reported enrollment target (1033% higher). The listed sponsor is ModernaTX, which has 90 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with SARS-CoV-2 appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT04470427 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Arizona, Alabama.

Frequently Asked Questions

What is clinical trial NCT04470427 about?

NCT04470427 is a clinical study titled "A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19". The mRNA-1273 vaccine is being developed to prevent COVID-19, the disease resulting from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection. The study is designed to primarily evaluate the efficacy, safety, and immunogenicity of mRNA-1273 to prevent COVID-19 for up to 2 years after...

What is the current status of trial NCT04470427?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 30,415 participants. The study started on 2020-07-27. Estimated completion is 2022-12-29.

What conditions does trial NCT04470427 study?

This clinical trial studies the following conditions: SARS-CoV-2.

What interventions are being tested in trial NCT04470427?

The interventions under investigation include: Placebo (BIOLOGICAL), mRNA-1273 (BIOLOGICAL).

Who is sponsoring clinical trial NCT04470427?

This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04470427 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for SARS-CoV-2

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

SARS-CoV-2

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.